Hepion Pharmaceuticals
Presença
Hepion Pharmaceuticals é uma empresa listada sob o símbolo HEPA (US).
Executivos
Veja o organograma con seus 12 executivos principais
Biografias mais buscadas da Hepion Pharmaceuticals
- John Cavan, Chief Financial Officer and Interim Chief Executive Of...
- Gary Jacob, Chairman of the Board
- John Brancaccio, Director
Recentes movimentos de executivos em Hepion Pharmaceuticals
- Michael Purcell, ingressou na Companhia como Director (Notícia publicada em 7 de março de 2024).
- Robert Foster, Chief Executive Officer and Director, deixou a Companhia (Notícia publicada em 7 de dezembro de 2023).
- John Cavan antes Chief Financial Officer, foi promovido a Chief Financial Officer and Interim Chief Executive Officer (Notícia publicada em 7 de dezembro de 2023).
Clique aqui para ver outras movimentos em Hepion Pharmaceuticals
Criar um alerta
para seguir os movimentos de executivos da Hepion Pharmaceuticals.
Farmacêutica
Hepion Pharmaceuticals possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Hepion Pharmaceuticals
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat – Hepion Pharmaceuticals
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer – Hepion Pharmaceuticals
- View more press releases Close
Redes sociais sobre Hepion Pharmaceuticals
- Hepion Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Hepion Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo John Cavan 
Ligue para a Hepion Pharmaceuticals em +1 212...
